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to Primary Percutaneous Coronary Intervention
for Acute ST-Segment Elevation Myocardial Infarction
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Objectives The purpose of this study was to investigate whether FX06 would limit infarct size when given as an adjunct to
percutaneous coronary intervention.
Background FX06, a naturally occurring peptide derived from human fibrin, has been shown to reduce myocardial infarct size
in animal models by mitigating reperfusion injury.
Methods In all, 234 patients presenting with acute ST-segment elevation myocardial infarction were randomized in 26
centers. FX06 or matching placebo was given as intravenous bolus at reperfusion. Infarct size was assessed 5
days after myocardial infarction by late gadolinium enhanced cardiac magnetic resonance imaging. Secondary
outcomes included size of necrotic core zone and microvascular obstruction at 5 days, infarct size at 4 months,
left ventricular function, troponin I levels, and safety.
Results There were no baseline differences between groups. On day 5, there was no significant difference in total late
gadolinium enhanced zone in the FX06 group compared with placebo (reduction by 21%; p  0.207). The ne-
crotic core zone, however, was significantly reduced by 58% (median 1.77 g [interquartile range 0.0, 9.09 g] vs.
4.20 g [interquartile range 0.3, 9.93 g]; p  0.025). There were no significant differences in troponin I levels (at
48 h, 17% in the FX06 group). After 4 months, there were no longer significant differences in scar size. There
were numerically fewer serious cardiac events in the FX06-treated group, and no differences in adverse events.
Conclusions In this proof-of-concept trial, FX06 reduced the necrotic core zone as one measure of infarct size on magnetic
resonance imaging, while total late enhancement was not significantly different between groups. The drug ap-
pears safe and well tolerated. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury [F.I.R.E.];
NCT00326976) (J Am Coll Cardiol 2009;53:720–9) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.017M
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February 24, 2009:720–9 The F.I.R.E. Trialmmediate reopening of acutely occluded coronary arteries by
rimary percutaneous coronary intervention (PCI) is the treat-
ent of choice to salvage ischemic myocardium in the setting
f ST-segment elevation myocardial infarction (STEMI) (1).
owever, the sudden reinitiation of blood flow can lead to
urther endothelial and myocardial damage (reperfusion injury)
2). Although reperfusion injury has been recognized for 30
ears, its underlying mechanism is not fully known.Membrane
amage induced by oxygen radicals, intracellular calcium over-
oad, opening of mitochondrial permeability transition pores,
nd tissue injury related to infiltration of white blood cells may
lay crucial roles (3,4).
See page 730
Most pharmacological strategies to mitigate reperfusion
njury have not been successful in clinical trials. These
nclude beta-blockers, glucose-insulin-potassium infusion,
odium-hydrogen exchange inhibitors, adenosine, calcium-
hannel blockers, potassium–adenosine triphosphate chan-
el openers, antibodies against leukocyte adhesion mole-
ules, and oxygen free radical scavengers (5). Recent trials,
ith a monoclonal antibody directed against complement
5 (6) and a protein kinase C inhibitor (7), were disap-
ointing. Adenosine reduced anterior infarct size when used
t high doses (8); however, a review of 5 trials (including the
MISTAD [Acute Myocardial Infarction Study of Aden-
sine] I and II studies) failed to show significant benefit (5).
n a report of 2 studies, atrial natriuretic peptide reduced
nfarct size as estimated by creatine kinase (9). The work in
his field has been comprehensively summarized (5). In
ontrolled trials, post-conditioning (10) and cyclosporine
11) reduced infarct size.
FX06 is a naturally occurring peptide derived from
uman fibrin (sequence B15-42) (12). It is a 28 amino
cid cleavage product of fibrin, which is released from
brin E1 fragments by plasmin and is an indicator of
brinolytic activity (13). In animal models for coronary
schemia/reperfusion, FX06 reduced infarct sizes (14–
6). In global reperfusion injury, such as hemorrhagic
hock followed by resuscitation, FX06 reduced organ
amage (17). FX06 competes with E1 fragments of fibrin
or binding to an endothelial specific molecule, VE-
adherin, thereby acting as an anti-inflammatory (14),
nd it signals through VE-cadherin, thereby reducing
lasma leakage into tissues (P. Petzelbauer, personal
ommunication, June 2008).
A phase I study in humans showed that FX06 was safe
nd well tolerated in doses of 50 to 1,350 mg (15). The
lasma half-life ranged from 11 to 17 min. Our aim in the
.I.R.E (Efficacy of FX06 in the Prevention of Myocardial
eperfusion Injury) study was to evaluate the cardioprotec-
ive efficacy of FX06 as an adjunct to primary PCI in
atients with acute STEMI.ethods
atients. Between October
006 and March 2008, we con-
ucted a randomized, double-
lind, placebo-controlled study.
he rationale and study design
ave been published (18). Briefly,
his study included patients with
first STEMI from a single
ulprit lesion and no other se-
ious comorbidities undergoing
rimary PCI as indicated per
tandard of care (Fig. 1) (1).
dditional inclusion criteria
ere presentation within 6 h of
nset of symptoms, 2 mm ST-
egment elevation in at least 3
lectrocardiogram (ECG) leads,
nd a single culprit lesion with TIMI (Thrombolysis In
yocardial Infarction) flow grade 0/1 in the infarct-related
rtery. Patients with prolonged ischemic symptoms, cardio-
enic shock, peripheral vascular disease, and history of
idney (serum creatinine 250 mol/l) or liver dysfunction
ere excluded. Written informed consent was obtained
Inclusion criteria
First myocardial infarction with PCI indicated 
per standard of care, within 6 hrs of onset of 
symptoms, >2 mm ST-segment elevation in at 
least 3 leads in ECG, single index lesion with 
TIMI flow 0/1
↓
Informed consent obtained,
study drug (active or placebo) in 2 bolus 
injections 10 min apart at the time of reperfusion 
during the PCI procedure.
↓
In-hospital monitoring
CMR with LGE 5 days after PCI,
adverse events, rhythm monitoring, laboratory.
↓
Follow-up
Telephone contacts at months 1, 2 and 3
CMR with LGE at 4 months
adverse events
Figure 1 Study Design
CMR  cardiac magnetic resonance imaging; ECG  electrocardiogram; LGE 
late gadolinium enhanced; PCI  percutaneous coronary intervention; TIMI 
Thrombolysis In Myocardial Infarction.
Abbreviations
and Acronyms
ANCOVA  analysis of
covariance
CMR  cardiac magnetic
resonance imaging
ECG  electrocardiogram
IQR  interquartile range
LGE  late gadolinium
enhanced
MVO  microvascular
obstruction
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
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The F.I.R.E. Trial February 24, 2009:720–9rom all patients. All patients were followed up clinically for
months.
rocedures. Eligible patients were randomly assigned to 1
f the 2 treatment groups using a computer-generated
andomization scheme. FX06 (400 mg) was administered in
intravenous bolus injections of 200 mg each during PCI,
he first immediately before the guidewire passed the
cclusion and the second 10 min (5 min) later (Fig. 1).
oncomitant therapies were allowed except for thrombo-
ytics and adenosine (Table 1). Infarct size was measured at
days (range 5 to 7 days) and 4 months after PCI using late
adolinium enhanced (LGE) cardiac magnetic resonance
maging (CMR).
The CMR examination involved an ECG-triggered ac-
uisition of a stack of short-axis slices covering the entire
eft ventricle from the base to the apex using a state-of-the-
atient Characteristics:ntent- o-Tre t Population (n  227)
Table 1 Patient Characteristics:Intent-to-Treat Population (n  227)
FX06
(n  110)
Placebo
(n  117)
Age, yrs, mean (SD) 59.8 (11) 59.6 (11)
Men 80 (73%) 95 (81%)
Body mass index, kg/m2, mean (SD) 27.6 (4.2) 27.4 (3.8)
Hypercholesterolemia 15 (14%) 19 (16%)
Diabetes mellitus 13 (12%) 12 (10%)
Hypertension 44 (40%) 45 (39%)
Regular smoker 48 (44%) 58 (50%)
Family history of coronary artery disease 20 (18%) 20 (17%)
Infarct location
Anterior 50 (46%) 55 (47%)
Nonanterior 59 (54%) 61 (52%)
Time to PCI, h, median (IQR) 3.1 (2.2–4.5) 3.1 (2.1–4.4)
3 h 53 (48%) 55 (47%)
At least 3 h 55 (50%) 60 (51%)
TIMI flow before PCI (grade)
0 90 (82%) 103 (88%)
1 19 (17%) 14 (12%)
2 or 3 1 (1%) 0 (0%)
TIMI flow after PCI (grade)
0 or 1 0 (0%) 3 (3%)
2 6 (6%) 8 (7%)
3 103 (94%) 105 (90%)
Presence of collaterals
Yes 26 (24%) 20 (17%)
No 82 (75%) 95 (81%)
Systolic BP at screening, mm Hg,
mean (SD)
136 (25) 139 (24)
Diastolic BP at screening, mm Hg,
mean (SD)
83 (14) 81 (17)
Concomitant medication
Acetylsalicylic acid 103 (94%) 111 (95%)
Clopidogrel 110 (100%) 117 (100%)
Beta-blockers 110 (100%) 116 (99%)
Agents acting on RAS 100 (91%) 111 (95%)
Intravenous GP IIb/IIIa inhibitors 59 (54%) 64 (55%)
P  blood pressure; GP  glycoprotein; IQR  interquartile range; PCI  percutaneous coronary
ntervention; RAS  renin-angiotensin system; TIMI  Thrombolysis In Myocardial Infarction.rt, steady-state, free-precession pulse sequence. The imag- mng parameters were as follows: slice thickness of 8 mm, no
ap between slices, temporal resolution 50 ms, matrix 224
o 256  224 to 256 using magnetic resonance scanners
rom all major vendors operating at 1.5 Tesla. In addition,
ong-axis 2-, 3-, and 4-chamber views were acquired with
he same parameter settings. Then, a contrast medium dose
f 0.25 mmol/kg was used (19,20). After 20 min, ECG-
riggered segmented inversion-recovery gradient echo
mages were acquired in the same slice orientations. The
ose of contrast medium was chosen to expand the
indow for viability imaging, facilitate data acquisition,
nd account for the multiple centers (with variable
xperience in CMR).
To acquire LGE images, inversion time was adjusted in
ach patient to null the signal of normal myocardium
19,21). The LGE imaging was obtained in mid to late
iastole to minimize motion by adjusting the trigger delay
450 ms). Other imaging parameters were as follows: slice
hickness of 8 mm without gap, matrix 192 to 256  192 to
56, and flip angle 20°.
Before participation, centers were asked to submit a series
f consecutive CMR images for quality control purposes.
ll images were analyzed at the central site by a single,
linded, experienced CMR reader followed by blinded
eview by a level III CMR expert (P.B. or J.B.). In the case
f discordance between the primary and expert reviewer,
onsensus was reached. Intraobserver variability was as-
essed in a subset of 40 randomly chosen studies and the
ntraclass correlation was 0.85 for 26 studies from day 5.
hat is higher than the critical value of 0.7 that was fixed
efore this examination (22).
Using short-axis cine loops of the left ventricle from base
o apex, endocardial and epicardial contours were traced
anually in each slice at end systole and end diastole to
easure areas. Left ventricular end-systolic and -diastolic
olumes, ejection fraction, and myocardial mass were cal-
ulated in a standard fashion (23).
All short-axis slices were assessed for areas of signal
nhancement. Areas with a very bright signal, namely, white
reas, were designated as the necrotic core zone, where the
ajority of myocytes are damaged beyond repair (24,25).
his necrotic bright area often contains a dark core where
here is no penetration of contrast medium, designated as
he microvascular obstruction (MVO) zone (26,27). The
VO zones were included in the measurement of the
ecrotic core zone. In addition, an infarct border zone was
etected with signal intensity higher than in normal myo-
ardium with “nulled” signal, but lower than in the necrotic
ore zone. This infarct border zone characterizes an injury
one with a variable portion of irreversibly damaged myo-
ytes (25,28). All 3 zones were separately measured, and
otal volumes were obtained by summing compartments of
ll slices covering the entire left ventricle. All volumes and
asses were also expressed as a percentage of left ventricular
yocardial mass.
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February 24, 2009:720–9 The F.I.R.E. TrialThe pre-defined primary end point was the difference
etween FX06- and placebo-treated patients in infarct size,
efined as the total LGE mass (necrotic core, MVO, and
nfarct border zones) after 5 days (Fig. 2). Secondary end
oints were prevalence of MVO zone at 5 days, as well as
eft ventricular function, troponin I levels, and safety at 5
ays and 4 months.
tatistical analysis. Sample size calculations for the pri-
ary end point were based on an expected infarct size of
8% of the left ventricle in the placebo group. With an
xpected reduction of 25% and a common SD of 11%, 95
atients in each group were required to detect a 4.5%
reatment difference with a 2.5% 1-sided significance and
0% power.
The primary end point was analyzed using an analysis of
ovariance (ANCOVA), with treatment, location of infarct
anterior/nonanterior), TIMI flow grade 0/1 before PCI
assessed in a blinded fashion by the investigator), presence
f collaterals (assessed in a blinded fashion by the investi-
ator using the Rentrop scale), time between onset of
ymptoms and first treatment injection (3 or 3 h), and
nteractions between treatment and the other factors as
ontrol variables. Missing values for control variables were
eplaced by pre-established rules that represent a worst-case
cenario: missing ECG at baseline was replaced with ECG
hortly after PCI to determine location of infarct, missing
IMI flow grade before PCI was set as TIMI flow grade 1,
issing data on presence of collaterals was set as collaterals
resent, and missing data on time between occurrence of
MVO zone
necrotic core zone
total LGE zone
normal myocardium
LV lumen
Figure 2 3 Different Zones on LGE CMR Images of Infarcts
Three different zones—microvascular obstruction (MVO) zone (red arrows),
necrotic core zone (green arrows), and total LGE zone (purple arrows)—on
LGE CMR images of infarcts are shown. Image is from 5 days after myocardial
infarction. This image is for representational purposes only, as not all patient
images look the same. LV  left ventricle; other abbreviations as in Figure 1.ymptoms and first injection of therapy was set as 3 h. hThe final ANCOVA model was derived using a stepwise
rocedure. The complete model was analyzed, and all
actors with an impact on the primary variable (p 0.2) and
he treatment were pre-selected. Using the pre-selected
actors, a stepwise backward selection was performed until
ll remaining factors other than treatment showed a p value
0.1. This final model was used to calculate the treatment
ffects and test for the superiority of FX06 using adjusted
eans. In addition, the 1-sided 97.5% confidence interval
as calculated.
The values of the zones of damaged left ventricular mass
nd the other left ventricular function measurements were
ompared between treatments using a 1-sided Wilcoxon
ank sum test at the 2.5% level (i.e., significant at p 0.025)
fter 5 days and 4 months. Mean, SD, median, and
nterquartile range (IQR) were derived but only the latter 2
re reported, as we used a nonparametric testing approach.
or biomarker levels, mean and SD are given. For safety
utcomes, frequencies were calculated and compared be-
ween treatments by the Fisher exact test at the 2-sided 5%
evel. All efficacy results are reported for the intent-to-treat
opulation, and adverse events are reported for the safety
opulation. All p values for secondary analyses are only
nterpreted in an exploratory manner.
esults
s shown in Figure 3, 252 patients were screened, and 234
ere randomized at 26 European centers. Thirteen patients
ere excluded who had no single index lesion and complete
cclusion (TIMI flow grade 0/1) of 1 target vessel, 2
atients in whom PCI was not possible or indicated, 1
atient whose myocardial infarction was not the first, 1
atient who needed coronary artery bypass graft surgery,
nd 1 patient who had an implanted device.
There were no significant differences between the groups
n patient characteristics (Table 1). Median time from
ymptom onset to treatment was 3.1 h in both groups.
pproximately 45% of patients had anterior infarcts. Essen-
ially, all patients received aspirin, clopidogrel, and beta-
lockers, and nearly one-half received glycoprotein IIb/IIIa
nhibitors.
Overall, 94 patients treated with FX06 and 104 patients
reated with placebo completed the trial, 78 patients with
X06 and 89 patients with placebo, respectively, had repeat
MR studies (Fig. 3). For analysis by the ANCOVA
odel, 93 patients treated with FX06 and 103 patients
reated with placebo were included (1 patient in each group
as lost due to protocol violations). The location of infarct
p  0.001) and the presence of collaterals (p  0.029)
nfluenced infarct size. The adjusted means for the total
GE zone (in % of left ventricle) were not different between
roups (19.71% for FX06 vs. 19.79% for placebo, 97.5%
onfidence interval: 4.08% to ; p  0.4849). However,
ased on data distribution in total LGE zone, outliers may
ave had an influence on results. A box plot analysis
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The F.I.R.E. Trial February 24, 2009:720–9evealed 4 outliers with an infarct size60%: 1 in the FX06
roup and 3 in the placebo group. Therefore, in the
ollowing data analyses, a nonparametric approach was used.
The results of the CMR measures for both 5 days and 4
onths are shown in Table 2. As there was a slight imbalance
234 randomize
received medication 
(FX06 114, Plac
252 patien
screened
227 eligib
(intent-to-tr
94 completed follow-up 
78 with CMR*
94 with CMR* after 5 days
110 assigned FX06
Figure 3 Trial Profile
*Number of patients for whom infarct sizes as measured by cardiac magnetic reso
the number of patients for whom other results are available may differ. ECG  ele
Results for Measures of Cardiac Magnetic Reso
Table 2 Results for Measures of Cardiac Ma
FX06
(n  94)
After 5 days
Total LV mass, g 145.0 (121.5–167
Total LGE zone, g 21.7 (8.3–47.1)
Total LGE zone, % of LV 16.1 (6.1–29.1)
Necrotic core zone, g 1.77 (0–9.09)
Necrotic core zone, % of LV 1.37 (0–6.12)
LV ejection fraction, % 47.2 (40.3–55.4)
Cardiac output, ml/min 4,406 (3,662–5,25
After 4 months (n  78)
Total LV mass, g 134.7 (116.7–158
Total LGE zone, g 15.4 (5.7–38.3)
Total LGE zone, % of LV 11.4 (5–24)
Necrotic core zone, g 2.31 (0–9.06)
Necrotic core zone, % of LV 1.67 (0–6.06)
LV ejection fraction, % 49.6 (42.4–56.4)
Cardiac output, ml/min 4,563 (3,717–5,32Data shown as median (interquartile range). *2-sided p value.
LGE  late gadolinium enhanced; LV  left ventricle.f total left ventricular mass between the treatment groups after
days, both the absolute weight of the zone and the normal-
zation with respect to the mass of the left ventricle are given.
fter 5 days, the median value of the total LGE zone was not
ignificantly different between groups (reduced by 21% for
d
ty population)
20)
18 not randomized
7 not eligible
- 3 not first MI
- 3 no evidence of MI in baseline ECG
- 1 cardiogenic shock
4 with CMR* after 5 days
117 assigned Placebo
04 completed follow-up
89 with CMR*
imaging (CMR) are available;
rdiogram; MI  myocardial infarction.
e Imaging After 5 Days
ic Resonance Imaging After 5 Days
Placebo
(n  104)
Treatment Effect
(1-Sided p Value)
154.3 (129.2–174.1) 0.185*
27.3 (11.7–44.9) 21% (0.207)
17.3 (9.3–27.1) 6.5% (0.311)
4.20 (0.3–9.93) 58% (0.019)
2.80 (0.18–6.22) 51% (0.023)
46.8 (41.2–53.0) 	0.8% (0.455)
4,474 (3,910–5,282) 1.5% (0.749)
(n  89)
135.4 (110.1–156.5) 0.907*
19.3 (7.5–31.4) 20% (0.363)
14 (6.9–23.9) 19% (0.226)
2.67 (0.33–7.00) 14% (0.328)
2.01 (0.21–4.82) 17% (0.289)
48.6 (42.4–55.5) 	2.1% (0.306)
4,503 (3,692–5,221) 	1.3% (0.314)d an
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February 24, 2009:720–9 The F.I.R.E. Trialissue weight in FX06). MVO was present in 27.6% of FX06
atients versus 37.5% of placebo patients (p  0.093). A
tatistically significant difference was seen in both the absolute
ass (1.77 g vs. 4.2 g, p  0.025) (Fig. 4) and the relative
ize (1.37% vs. 2.8%, p  0.025) (Fig. 5) of the necrotic
ore zone with FX06 compared with placebo. The mass
nd size of this zone was more than halved (58% and
51%, respectively) (Fig. 4) with FX06 treatment. There
p <0.025* p = 0
0
10
20
30
40
50
21
(8.33-
0
1
2
3
4
5
1.77
(0-9.09)
4.20
(0.30-9.93)
N
ec
ro
ti
c 
co
re
 z
o
n
e
(g
)
T
o
ta
lL
G
E
 z
o
n
e
(g
)
FX06 Placebo FX
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ther CMR parameters (Table 2).
After 4 months, CMR revealed no significant differences
n total LGE zones (20% reduction in tissue mass or 19%
eduction in % of left ventricle in the FX06 group) or
ecrotic core zones (14% reduction in tissue mass or 17%
eduction of % of left ventricle in the FX06 group). Because
15% of patients did not have a repeat CMR at 4 months,
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The F.I.R.E. Trial February 24, 2009:720–9his result might not be comparable to the early end point
wing to disparity between the treatment groups in the
haracteristics of patients without repeat measurements.
Pre-specified subgroup analyses were performed using the
uspected control variables for selection (i.e., anterior vs.
onanterior infarcts, time to balloon 3 h vs. 3 h).
lthough infarct location, time to presentation, and pres-
nce of collaterals had some influence on the result, there
as no deviation from the overall effect in the subgroups.
easurements of biomarkers of myocyte necrosis revealed
o significant differences in the placebo group and the FX06
roup in mean troponin I values at 24 h (55.4 ng/ml [SD
2.8 ng/ml] and 49.6 ng/ml [SD 39.7 ng/ml], p  0.195),
ean troponin I at 48 h (26.4 ng/ml [SD 22.8 ng/ml] and
1.8 ng/ml [SD 17.1 ng/ml], p  0.091), and creatine
inase–myocardial band activity at 90 min after PCI (4.34
kat/l [SD 3.79 kat/l] and 3.65 kat/l [SD 3.06 kat/l]).
Safety data and clinical outcomes at 4 months are shown
n Table 3. There were no differences in treatment-related
dverse events between groups. Seven adverse events in each
roup resulted in premature discontinuation. In the FX06
roup, these included 6 events assessed as unrelated to the
tudy drug (malignant neoplasm, coronary artery disease
ith mitral valve incompetence, circulatory collapse, cardiac
rrest, cardiac failure, and metastatic neoplasm), as well as 1
vent assessed as possibly related to the study drug (cardio-
enic shock). The number of cardiovascular-related serious
dverse events was numerically lower in the FX06 group
han in the placebo group (n  21 vs. 29) (Table 4).
There was no increased risk of life-threatening arrhyth-
ias (ventricular fibrillation/tachycardia), conduction disor-
ers (third-degree atrioventricular block), stent thrombosis,
r hypotension. There were 3 cases of hypotension in the
lacebo group and 4 (1 orthostatic) in the FX06 group.
All-cause mortality was 2.6% (3 of 114) in the FX06
roup and 4.2% (5 of 120) in the placebo group. There were
cases of nonfatal heart failure or pulmonary edema in the
X06 group and 5 in the placebo group. All deaths, except
in the FX06 group (metastatic prostate cancer not iden-
ified at study inclusion), were due to cardiac causes. One
eath due to bradycardia with pulseless electric activity
Safety Data and Clinical Outcomes
Table 3 Safety Data and Clinical Outcomes
Treatment-emergent adverse events
Treatment-emergent adverse events leading to premature d
Treatment-emergent serious adverse events
Treatment-emergent serious adverse events leading to prem
Death
Cardiac death
Composite of cardiac death and new onset heart failure/pu
Data presented as n (%) of patients.ccurred 13 days after PCI (placebo group). The other 6 uardiac deaths occurred between 1 and 4 days after PCI,
rimarily due to acute heart failure and cardiogenic shock.
iscussion
he F.I.R.E study, conducted as an exploratory proof-of-
oncept study among patients with STEMI treated with
rimary PCI, did not meet the primary end point of LGE
one reduction. However, the necrotic core zone—which
ight have been a more reasonable definition of “infarct
ize”—was significantly reduced, suggesting that FX06
ends to reduce at least one, and perhaps the most impor-
ant, measure of infarct size as predicted from pre-clinical
ata (14–16). Other measurements and observations were
egative in statistical terms; however, they all showed a
umerically consistent trend in favor of FX06.
Although a variety of strategies have suggested reductions
f reperfusion injury in animal models, most have not
roduced significant myocardial protection in humans.
hese failed interventions have been extensively reviewed by
irksen et al. (5). The DELTA-MI (Direct Inhibition of
-Protein Kinase C Enzyme to Limit Total Infarct Size in
cute Myocardial Infarction) study with protein kinase C
nhibitor KAI9803 delivered equivocal results (5,7). Atrial
atriuretic peptide (9), post-conditioning (10), and cyclo-
porine (11) have been associated with reduced infarct size.
FX06
(n  114)
Placebo
(n  120)
2-Sided
p Value
100 (87.7%) 97 (80.8%) 0.157
inuation 7 (6.1%) 7 (5.8%) 1.0
37 (32.5%) 31 (25.8%) 0.314
discontinuation 7 (6.1%) 6 (5.0%) 0.78
3 (2.6%) 5 (4.2%) 0.723
2 (1.8%) 5 (4.2%) 0.447
ry edema 5 (4.4%) 8 (6.7%) 0.572
ardiovascular-Related Serious Adverse Events
Table 4 Cardiovascular-Related Serious Adverse Events
Number of Events
FX06 Placebo
Cardiac death 2 5
Heart failure (nonfatal)/pulmonary edema 3 5
VT/VF, life-threatening arrhythmia 5 7
Atrioventricular block third-degree 2 2
Acute coronary syndrome (STEMI/non-STEMI) 3 4
Acute stent thrombosis 2 2
Revascularization 2 2
Intraventricular thrombus 1 1
Noncardiac major vascular events 1* 1†
Total 21 29
Acute peripheral ischemia. †Stroke.iscont
ature
lmonaSTEMI  ST-segment elevation myocardial infarction; VF  ventricular fibrillation; VT  ventric-
lar tachycardia.
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February 24, 2009:720–9 The F.I.R.E. TrialThe significant effects on the necrotic core zone with
X06 are likely due to its dual mode of action through
E-cadherin. VE-cadherin regulates traffic of cells and
uids across endothelial barriers from the lumen into tissues
29,30). FX06 competes with fibrin fragments for binding
o VE-cadherin, reducing leukocyte migration and tissue
nflammation (14). Additionally, FX06 stabilizes endothe-
ial cell junctions by signaling through VE-cadherin, reduc-
ng vascular leak and tissue edema (P. Petzelbauer, personal
ommunication, July 2008); both effects may improve cap-
llary flow. Improvement of capillary flow may explain the
lightly lower incidence of MVO in FX06 patients. In this
ontext, the presence of MVO has been found to be a strong
redictor of unfavorable patient outcome (27).
The periprocedural dosing of FX06 is critical to achieve
aximum plasma levels at the time of reperfusion, which is
onsidered a trigger event for injury early after blood flow is
e-established (31). The dosing of FX06 was based on
harmacokinetics; with a plasma half-life of 11 to 17 min, 2
njections within 10 min would maintain therapeutic levels
or up to 45 min (15). Administration at 60 min after
eperfusion did not reduce infarct size in animal models (16).
The FX06 treatment was well tolerated in this study, with
o unexpected drug toxicity compared with placebo. On the
ontrary, the composite outcome of cardiac death and
ew-onset heart failure/pulmonary edema was slightly lower
n the FX06 group (4.4%, 5 of 114) than in the placebo
roup (6.7%, 8 of 120). Although the F.I.R.E. study was
ot powered to detect a significant difference in clinical
utcomes, it is noteworthy that the incidences of cardiac
eath, all serious adverse cardiac events, and new-onset
eart failure were all in favor of the FX06 treatment.
The primary end point showed a trend toward smaller
nfarct size but did not achieve statistical significance, and
hat may be due to an inadequate sample size. The sample
ize was calculated based on an SD of 11% associated with
reduction in infarct size of 25%, whereas the observed SD
n the data was 16% and the reduction was 21%. That leads
o a post-hoc power of 59%, with an infarct reduction of
5%. With the lower reduction, the statistical power was
ven lower.
Infarct size measured at hospital discharge predicted
hort-term (32) and 2-year mortality (33). Until recently,
tudies correlating infarct size with clinical outcomes used
ingle-photon emission computed tomography, but CMR is
ow considered the most accurate modality (34,35). A large
tudy evaluating the prognostic value of CMR in 1,493
atients found that age, left ventricular ejection fraction,
nd extent of scar tissue were independent predictors of
ll-cause mortality (36). These findings were confirmed in a
-year trial using CMR in 122 patients (37). As in the
.I.R.E. study, CMR was used in a trial to assess global left
entricular function and infarct size after stem cell transfer
fter successful primary PCI for STEMI (38).
CMR allows high spatial resolution, and the total LGEone can be differentiated into necrotic core, MVO, and pnfarct border zones. The prognostic significance of the
nfarct border zone is unclear (39), but the necrotic core
one undoubtedly represents nonviable myocardium. This
one was where FX06 exerted its single significant effect
fter 5 days; however, this effect was not significant after 4
onths.
The beneficial effects on the necrotic core zone may
epresent an important outcome. Although the necrotic core
egions were small, they were similar to those in the study by
hiele et al. (40). Evidence suggests that when even a small
art of the left ventricle is permanently damaged, it can have
erious consequences for remodeling (41). Necrosis and scar
ize quantified by magnetic resonance imaging are docu-
ented to predict improvement of regional function after
evascularization and prognosis for major cardiovascular
vents (19,21,27,42–44). That observation is underlined by
VO, which affects an even smaller part of the myocar-
ium, having also been shown to be an independent
redictor of adverse patient outcome (41).
tudy limitations. Infarct size was quantified manually,
lthough all evaluations were performed in a blinded fash-
on, and consequently, a subjective bias was unlikely to
ccur.
Only a single dose of 400 mg during the PCI procedure
as used. Even though we were able to demonstrate a
ignificant reduction in the necrotic core zone, further
ose-finding studies are required to determine optimal
osing.
Effects of FX06 were significant on the necrotic core
one, but not on the infarct border zone. In previous trials
sing CMR, the reported values for infarct size were in
ccordance with published single-photon emission com-
uted tomography values (45). None of the studies using
MR to correlate infarct size with clinical outcomes or
tudies that measured infarct size for a treatment effect
eported the details of the respective zones of necrosis,
VO, or infarct border. Of note, adverse clinical outcomes
orrelate with infarct size only in large infarcts 12% of the
eft ventricle in earlier studies (26,27,32). A correlation
etween necrotic core size and clinical cardiovascular events
as not yet been assessed, which limits the interpretation
f our results.
Patients were followed for 4 months primarily for safety
easons, looking for cardiac death and major adverse cardiac
vents. A second CMR at this visit was done to assess
hether FX06 treatment had an effect on scar formation,
owever, it was unlikely that a significant effect would be
emonstrated since we did not control for confounding
ffects and medication during the follow-up period. This
as indeed the case: scar mass was numerically but not
ignificantly lower at the 4-month (visit 3) timepoint
ompared with placebo. The study design did not allow for
ny estimation of infarct expansion or shrinkage with
espect to necrotic core size at 5 days and scar size at 4
onths. More importantly, 15% of patients (FX06 n  14,
lacebo n  16) did not return for repeat CMR at 4
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The F.I.R.E. Trial February 24, 2009:720–9onths. This included five patients in the placebo group
nd 2 patients in the FX06 group who died from a cardiac
ause; since they probably had large infarctions, their loss to
ollow-up leads to a distortion. A further distortion is likely
ince patients without any symptoms post-PCI were lost to
ollow-up and larger infarcts were over-represented in the
X06-treated group at 4 months. Analysis of only patients
ith paired CMR showed no difference in infarct size
elative to LV mass in patients treated with FX06 at day 5
nd 4 months, whereas there appears to be a shrinkage in
he placebo patients. However, analysis of completers only
ntroduces another selection bias. It is possible that the
nfarcts of patients treated with FX06 were already so small
hat there was not much apparent shrinkage during remod-
ling (unlike under placebo), but such an interpretation
emains speculative.
onclusions
lthough this study did not show a significant reduction in
he total LGE zone, it did show a reduction of necrotic core
ize after injection of FX06 as an adjunct to standard care in
TEMI patients undergoing PCI. There were no signifi-
ant differences in biomarkers of myocardial necrosis and no
ignificant differences in scar size after 4 months, although
rends were positive. There was a lower incidence of serious
ardiovascular events in the FX06 group, but with numbers
oo small to prove beneficial clinical effects. These findings
arrant further scrutiny in an adequately powered dose-
nding and clinical outcome trial.
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